Research to date has indicated that cAMPspecific PDEs, particularly the members of PDE4 family, play a crucial role in the pathogenesis of CNS injury and neurodegeneration by downregulating intracellular levels of cAMP in various cell types. Reduced cAMP signaling results in immune cell activation, inflammation, secondary tissue damage, scar formation and axon growth failure, ultimately leading to an exacerbation of injury, the prevention of endogenous repair and limited functional recovery. Although inhibition of cAMPspecific-PDE activity through the use of drugs like Rolipram has been shown to reverse these deficiencies and mediate neurorepair, an inability to develop selective agents and/or reduce dose-limiting side-effects associated with PDE4 inhibition has hampered their clinical translation. Recent work with more selective pharmacological inhibitors of cAMP-specific PDEs and molecular targeting approaches, along with improved understanding of the basic biology and role of PDEs in pathological processes may enable this promising therapeutic approach to advance clinically and have a similar impact on CNS injury and disease as PDE5 inhibitors have had on the treatment of sexual dysfunction.
subcellular domains, allows compartmentalized cyclic nucleotide signaling [3] [4] in response to specific extracellular stimuli. From 11 different PDE families that have been characterized to date, which vary in cyclic nucleotide specificity, affinity, regulatory control and subcellular compartmentalization, there are eight PDE gene families that are capable of hydrolyzing cAMP, some of which hydrolyze cAMP exclusively and others both cAMP and cGMP [2, 5] . In the central nervous system (CNS), under normal physiological conditions, basal levels of cAMP degrading PDE4 have been shown within various regions of the brain and spinal cord, such as in the cerebral cortex, hippocampus, hypothalamus, striatum and the substantia nigra, both in neurons and glia; 6-8. For the other cAMP-specific PDEs; PDE7 and 8, high mRNA expression of both PDE7A
and PDE7B are seen in the rat brain. PDE7A is found in the olfactory bulb and tubercle, the hippocampus, particularly the granule cells of the dentate, and several brainstem nuclei [9] while the highest amount of PDE7B mRNA expression is observed in the cerebellum, striatal complex and the dentate gyrus of the hippocampus [10] [11] . The production of the PDE7s' respective proteins has not yet been reported. PDE8B mRNA has been shown to be present in the hippocampus and is elevated in patients with late-stage Alzheimer's disease [12] . However, as both PDE7 and PDE8 are cAMP-degrading PDEs, exhibiting 10-and 40-fold higher affinity than PDE4 respectively, it has led to speculation that these enzymes are largely involved in the regulation of basal (or low concentrations) versus stimulated levels of cAMP. Further studies are needed to examine basal protein levels of PDE7 and 8 isoforms in the CNS and to determine how they are altered after CNS injury and disease [13] .
In the acute phase of CNS injury, subsequent to mechanical trauma, various degenerative processes including neuron and oligodendrocyte cell death, axon axotomy and demyelination as well as the formation of cellular reactivity at the injury site contribute to loss of neurological function and abortive endogenous repair [14] . Tissue levels of cAMP have been shown to be reduced in experimental animal models of both traumatic brain [15] [16] and spinal cord injury (TBI or SCI; 16). These levels can be largely restored and the detrimental effects of injury partially reversed when the PDE4-specific inhibitor Rolipram is given. [15] [16] . Members of the PDE4 family have been found to play a key role in initiating neuroinflammation [15] [16] [17] , accelerating secondary tissue damage [18] and restricting the intrinsic ability of injured neurons to regenerate [16, 19] and/or be remyelinated [16] 
Regulation of cAMP-specific PDEs in the CNS following injury
Since cAMP-specific PDE activity in CNS tissue was first identified several decades ago, high isozyme expression levels for PDEs 1, 2, 4, and 10 have been reported in specific areas of the brain and the spinal cord following injury [7] .
The activity of these PDE's may be responsible for lowering intracellular levels of cyclic nucleotides, stimulating in turn the migration and activation of various immune cell populations; neutrophils, macrophages, and microglia [20] [21] [22] [23] , impairing blood brain barrier function and/or reducing neuronal activity and suppressing survival programs important for preventing cell death [21] . 
PDE4 inhibition for neurogeneration
Previous work with Rolipram from our group and others [15] [16] Studies have demonstrated that an elevation of cAMP in vitro allows axons to grow over inhibitory substrates [36] and is important for axon guidance and turning behaviors [37] ; conversely, decreases in cAMP levels are thought to occur during development, reducing intrinsic neuronal growth capacity and restricting plasticity in the adult organism.
Gao and colleagues [38] as an anti-depressant drug and later gained significant attention as a cognitive enhancer [25] and as an anti-inflammatory drug [39] . In recent years, Rolipram has shown efficacy in a number of CNS injury and neurodegenerative disorders, including SCI [16, 18, 26, 40] , TBI [15] as well as Huntington's [41] , Alzheimer's [42] and Parkinson's diseases [43] , highlighting the importance of PDE4 in the CNS. and V11294A have all been discontinued either due to lack of efficacy or a low therapeutic ratio due to adverse effects severely limiting their dose and potential effectiveness clinically [48] .
Despite the large number of PDE4 inhibitors that have been manufactured to date, the best clinical progress to date has been achieved with the oral, non-isoform selective PDE4 inhibitors cilomast and roflumilast [49] , which have been recently approved by the FDA for COPD and asthma. 
